Oleclumab - MedImmune

Drug Profile

Oleclumab - MedImmune

Alternative Names: Anti-CD73 MAb; Anti-CD73 monoclonal antibody; MEDI-9447

Latest Information Update: 13 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MedImmune
  • Developer European Network of Gynaecological Oncological Trial Groups; MedImmune
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action 5-Nucleotidase-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ovarian cancer
  • Phase I/II Non-small cell lung cancer; Pancreatic cancer
  • Phase I Solid tumours

Most Recent Events

  • 13 Aug 2018 Nordic Society for Gynaecologic Oncology plans a phase trial for Ovarian cancer (Late-stage disease, Combination therapy) (NCT03267589)
  • 06 Aug 2018 AstraZeneca plans the SYNERGY phase III trial for Breast cancer (First-line therapy, Recurrent, Unresectable/Inoperable) in October 2018 (NCT03616886)
  • 02 Aug 2018 Phase-I/II clinical trials in Pancreatic cancer (First-line therapy, Combination therapy, Metastatic disease) in USA (Parenteral) (NCT03611556)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top